期刊文献+

“零对比剂”经皮冠状动脉介入治疗对重度肾功能不全患者的安全性及有效性分析 被引量:8

Safety and effi cacy analysis for percutaneous coronary intervention without contrast administration in severe renal failure patient
下载PDF
导出
摘要 目的探讨重度肾功能不全患者行“零对比剂”经皮冠状动脉介入治疗(PCI)的安全性及有效性。方法对2018年1月至2019年12月上海市普陀区中心医院收治的16例重度肾功能不全[估算的肾小球滤过率(eGFR)<30 ml/(min·1.73 m^(2))]的心绞痛或非ST段抬高型心肌梗死患者在血管内超声(IVUS)指导下行“零对比剂”PCI的临床资料进行回顾性分析。结果16例重度肾功能不全患者的eGFR为(21.4±6.8)ml/(min·1.73 m^(2)),使用对比剂(25.0±3.8)ml以确定冠状动脉病变,于IVUS指导下行“零对比剂”PCI,术中支架定位确切,扩张满意,未出现夹层,最终所有患者心肌梗死溶栓治疗试验血流分级为Ⅲ级。16例重度肾功能不全患者PCI术后24 h eGFR、肌酐、肌红蛋白、肌酸激酶同工酶及心肌肌钙蛋白I与术前相比,差异均无统计学意义(均P>0.05);住院期间无再次心肌梗死、心绞痛等症状发生。3个月随访,无不良心血管事件发生。结论重度肾功能不全患者经IVUS指导行“零对比剂”PCI是安全有效的。 Objective In this study,we discuss the safety and efficacy for percutaneous coronary intervention(PCI)without contrast agent in severe renal failure patient.Methods 16 patients for angina pectoris or NSTEMI with severe renal failure[eGFR<30 ml/(min·1.73 m^(2))]were admitted to our hospital from January 2018 to December 2019.The clinical data of PCI with zero contrast under the guidance of IVUS were analyzed retrospectively.Results 16 patients with severe renal failure[eGFR(21.4±6.8)ml/(min·1.73 m^(2))],used the minimum dose of isotonic contrast agent(25.0±3.8)ml to identify coronary lesions.PCI without contrast was successfully performed in all patients under the guidance of IVUS.During the operation,the stent location was accurate,the expansion was satisfactory,and there was no dissection.Finally,TIMI blood fl ow was gradeⅢafter operation.There were no signifi cant diff erences for 16 patients in terms of the levels of their eGFR,creatinine,enzymes in 24 h after PCI than before(all P>0.05);There was no reinfarction and angina pectoris during hospitalization.There was no cardiac event during the three-month follow-up.Conclusions PCI with zero contrast guided by IVUS is safe and eff ective in patients with severe renal failure.
作者 胡文瑛 严鹏勇 王睿 王超凡 金惠根 刘宗军 汪志华 HU Wen-ying;YAN Peng-yong;WANG Rui;WANG Chao-fan;JIN Hui-gen;LIU Zong-jun;WANG Zhi-hua(Department of Cardiology,Putuo District Central Hospital,Shanghai 200062,China)
出处 《中国介入心脏病学杂志》 2021年第7期371-374,共4页 Chinese Journal of Interventional Cardiology
基金 上海市普陀区卫生健康系统临床医学优势学科(2019ysxk01)。
关键词 经皮冠状动脉介入治疗 对比剂肾病 重度肾功能不全 血管内超声 Percutaneous coronary intervention Contrast-induced nephropathy Severe renal failure Intravascular ultrasound
  • 相关文献

参考文献2

二级参考文献26

  • 1邹古明,颜红兵.造影剂肾病的诊断与治疗现状[J].中国介入心脏病学杂志,2005,13(3):194-196. 被引量:78
  • 2李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 3Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 4Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 5Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 6CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 7Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 8Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 9Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.

共引文献2148

同被引文献59

引证文献8

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部